Ipsen has announced that Azzalure, a muscle relaxant developed for aesthetic use, has received marketing approval in France from the Agence Francaise de Securite Sanitaire des Produits de Sante.
The authorization is for marketing the drug’s ability to temporary improve in the appearance of moderate to severe glabellar lines seen at the frown, in adult men and women ages 65 years and under, who are psychologically affected by the severity of these lines.
Galderma will market Azzalure in France before the end of the first semester 2009. Under terms of their deal, established in 2007, Ipsen has given Galderma exclusive rights to develop, promote and distribute for aesthetic indications Azzalure — a specific formulation of its 20-year-old botulinum toxin type A product Dysport.
Galderma will pay up to 20 million euros to Ipsen upon the achievement of certain milestones, such as local market approvals and product launches. The company will also pay royalties on net sales to Ipsen.
Ipsen will manufacture and supply Galderma’s finished product at a fixed supply price.
[Source: RTT News]
